NeoPharm, Inc. (Nasdaq:NEOL) today announced the presentation of preliminary Phase I results of the Company's NeoLipid(R) formulation of c-raf Antisense Oligonucleotide at the American Association of Cancer Research (AACR) - National Cancer Institute (NCI) - European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics. The conference, the premier international meeting featuring novel cancer therapeutics, is being held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania from November 14-18, 2005.
